Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
GHRS Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GHRS Stock 12 Month Forecast
Average Price Target
$33.67
▲(187.78%Upside)
| Highest Price Target$40.00 | Average Price Target$33.67 | Lowest Price Target$29.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
―
Buy
―
Reiterated
05/09/25
Guggenheim
$32→$29
Buy
147.86%
Upside
Reiterated
05/09/25
H.C. Wainwright
$40
Buy
241.88%
Upside
Reiterated
05/09/25
RBC Capital
$31→$32
Buy
173.50%
Upside
Reiterated
05/08/25
Canaccord Genuity
$35
Buy
199.15%
Upside
Reiterated
02/27/25
Optimistic Buy Rating for GH Research Driven by Promising Clinical Data and Strong Financial OutlookWe note that resolving this hold is an important step in the company's ability to run clinical studies including US sites, and we look forward to the next steps on the GH001 program in TRD. With the blinded Phase 2b data now behind us, we view any updates on OLE data and/or a successful resolution of the FDA hold as having the potential to drive upside from here. Reiterate BUY. Separately, we will also be keeping a close watch on competitor ATAI/Beckley's Phase 2b data for BPL-003 (intranasal mebufotenin), which could come in mid-25.
Citizens JMP
$39
Buy
233.33%
Upside
Reiterated
02/27/25
Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Cullinan Management (CGEM)We remain confident that the company has generated all necessary preclinical data to fully address the FDA’s outstanding questions and confirm that toxicity findings in rats are species specific. Following this, we look to finalization of the Phase 3 protocol in TRD to be agreed upon with the FDA in 2H25.
Stifel Nicolaus
$18→$32
Buy
173.50%
Upside
Reiterated
02/26/25
Cantor Fitzgerald
$14
Buy
19.66%
Upside
Initiated
02/13/25
Rodman & Renshaw
$42→$36
Buy
207.69%
Upside
Reiterated
02/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
―
Buy
―
Reiterated
05/09/25
Guggenheim
$32→$29
Buy
147.86%
Upside
Reiterated
05/09/25
H.C. Wainwright
$40
Buy
241.88%
Upside
Reiterated
05/09/25
RBC Capital
$31→$32
Buy
173.50%
Upside
Reiterated
05/08/25
Canaccord Genuity
$35
Buy
199.15%
Upside
Reiterated
02/27/25
Optimistic Buy Rating for GH Research Driven by Promising Clinical Data and Strong Financial OutlookWe note that resolving this hold is an important step in the company's ability to run clinical studies including US sites, and we look forward to the next steps on the GH001 program in TRD. With the blinded Phase 2b data now behind us, we view any updates on OLE data and/or a successful resolution of the FDA hold as having the potential to drive upside from here. Reiterate BUY. Separately, we will also be keeping a close watch on competitor ATAI/Beckley's Phase 2b data for BPL-003 (intranasal mebufotenin), which could come in mid-25.
Citizens JMP
$39
Buy
233.33%
Upside
Reiterated
02/27/25
Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Cullinan Management (CGEM)We remain confident that the company has generated all necessary preclinical data to fully address the FDA’s outstanding questions and confirm that toxicity findings in rats are species specific. Following this, we look to finalization of the Phase 3 protocol in TRD to be agreed upon with the FDA in 2H25.
Stifel Nicolaus
$18→$32
Buy
173.50%
Upside
Reiterated
02/26/25
Cantor Fitzgerald
$14
Buy
19.66%
Upside
Initiated
02/13/25
Rodman & Renshaw
$42→$36
Buy
207.69%
Upside
Reiterated
02/07/25
Best Analysts Covering GH Research
1 Month
xxx
Success Rate
4/8 ratings generated profit
Average Return
-2.01%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -2.01% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
+1.33%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +1.33% per trade.
1 Year
Success Rate
6/8 ratings generated profit
Average Return
+7.49%
reiterated a buy rating 20 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +7.49% per trade.
2 Years
xxx
Success Rate
7/8 ratings generated profit
Average Return
+19.75%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +19.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GHRS Analyst Recommendation Trends
Rating
Nov 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
8
10
14
13
14
Buy
2
3
4
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
13
18
16
17
Each month's total comprises the sum of three months' worth of ratings.
GHRS Financial Forecast
GHRS Stock Forecast FAQ
What is GHRS’s average 12-month price target, according to analysts?
Based on analyst ratings, GH Research’s 12-month average price target is 33.67.
What is GHRS’s upside potential, based on the analysts’ average price target?
GH Research has 187.78% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GHRS a Buy, Sell or Hold?
GH Research has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is GH Research’s price target?
The average price target for GH Research is 33.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $29.00. The average price target represents 187.78% Increase from the current price of $11.7.
The highest analyst price target is $40.00 ,the lowest forecast is $29.00. The average price target represents 187.78% Increase from the current price of $11.7.
What do analysts say about GH Research?
GH Research’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of GHRS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.